This clinical trial aims to evaluate the effectiveness of a new medication for treating migraines. Participants will be randomly assigned to receive either the new medication or a placebo, which is a substance with no active therapeutic effect. The study seeks to determine if the new treatment can reduce the frequency and severity of migraine attacks compared to the placebo.
- Who Can Participate: Adults aged 18-65 who have been diagnosed with migraines and experience at least four migraine days per month
- Study Details: Participants will be randomly assigned to receive either the new medication or a placebo. The study will assess the medication's impact on the frequency and severity of migraines
- Study Timelines and Visits: The study will last 6 months.The study requires 5 visits
